Zynex, Inc. (ZYXI)
Stock Price:
$13.62 USD
0.20 (1.49%)
Updated November 23, 4:00 PM EST - Market closed
Key Info
| Market Cap |
473.17M |
| Revenue (ttm) |
68.68M |
| Net Income (ttm) |
10.23M |
| Shares Out |
34.74M |
| EPS (ttm) |
0.30 |
| PE Ratio |
45.40 |
| Forward PE |
43.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 23 |
| Last Price |
$13.62 |
| Previous Close |
$13.42 |
| Change ($) |
0.20 |
| Change (%) |
1.49% |
| Day's Open |
13.50 |
| Day's Range |
13.18 - 13.67 |
| Day's Volume |
339,302 |
| 52-Week Range |
7.51 - 29.73 |
More Stats
| Market Cap |
473.17M |
| Enterprise Value |
436.84M |
| Earnings Date (est) |
Mar 3, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.74M |
| Float |
19.45M |
| EPS (basic) |
0.31 |
| EPS (diluted) |
0.30 |
| FCF / Share |
0.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
2.20% |
| FCF Yield |
0.81% |
| Payout Ratio |
n/a |
| Shares Short |
6.18M |
| Short Ratio |
6.13 |
| Short % of Float |
31.76% |
| Beta |
0.91 |
| PE Ratio |
45.40 |
| Forward PE |
43.29 |
| P/FCF Ratio |
123.71 |
| PS Ratio |
6.89 |
| PB Ratio |
8.58 |
| Revenue |
68.68M |
| Operating Income |
11.68M |
| Net Income |
10.23M |
| Free Cash Flow |
3.83M |
| Net Cash |
36.33M |
| Net Cash / Share |
1.05 |
| Gross Margin |
53.55% |
| Operating Margin |
17.01% |
| Profit Margin |
14.90% |
| FCF Margin |
5.57% |
| ROA |
16.28% |
| ROE |
28.99% |
| ROIC |
64.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$25.75*
(89.06% upside)
Low
22.5
Current: $13.62
High
30.3
Target: 25.75
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 45.47 | 31.92 | 23.43 | 13.31 | 11.64 | 11.12 | 21.68 | 47.15 | 39.68 | 28.49 |
| Revenue Growth | 42.47% | 36.21% | 76.01% | 14.36% | 4.71% | -48.73% | -54.01% | 18.84% | 39.29% | - |
| Gross Profit | 36.66 | 25.88 | 18.61 | 9.80 | 6.70 | 3.51 | 13.54 | 38.38 | 32.31 | 23.28 |
| Operating Income | 11.07 | 10.37 | 8.94 | 0.64 | -2.48 | -5.70 | -7.60 | 10.22 | 8.63 | 5.96 |
| Net Income | 9.49 | 9.55 | 7.37 | 0.07 | -2.91 | -6.20 | -7.30 | 1.55 | 1.56 | 0.35 |
| Shares Outstanding | 32.44 | 32.50 | 32.16 | 31.27 | 31.27 | 31.21 | 31.15 | 31.06 | 30.75 | 30.55 |
| Earnings Per Share | 0.28 | 0.28 | 0.22 | - | -0.09 | -0.20 | -0.23 | 0.05 | 0.05 | 0.01 |
| EPS Growth | 0% | 27.27% | - | - | - | - | - | 0% | 400% | - |
| Dividend Per Share | - | 0.07 | - | - | - | 0.15 | - | - | - | - |
| Operating Cash Flow | 6.30 | 9.41 | 8.26 | 1.77 | 0.34 | 0.96 | -0.38 | -0.88 | -0.36 | -0.67 |
| Capital Expenditures | -0.16 | -1.08 | -0.09 | -0.23 | 0.01 | -0.27 | -0.64 | -0.76 | -1.27 | -0.67 |
| Free Cash Flow | 6.14 | 8.33 | 8.17 | 1.54 | 0.35 | 0.69 | -1.03 | -1.64 | -1.63 | -1.34 |
| Cash & Equivalents | 14.37 | 10.44 | 5.94 | 0.30 | 0.06 | 0.07 | 0.72 | 0.99 | 0.96 | 0.78 |
| Total Debt | 4.68 | 3.66 | 0.35 | 3.03 | 4.33 | 4.83 | 6.06 | 6.16 | 3.68 | 1.69 |
| Net Cash / Debt | 9.69 | 6.78 | 5.58 | -2.72 | -4.26 | -4.77 | -5.34 | -5.17 | -2.72 | -0.91 |
| Assets | 28.28 | 19.25 | 8.93 | 4.09 | 3.70 | 7.11 | 17.22 | 25.94 | 21.79 | 15.70 |
| Liabilities | 8.62 | 9.96 | 4.03 | 7.89 | 7.77 | 8.38 | 12.37 | 13.88 | 11.65 | 7.52 |
| Book Value | 19.74 | 9.38 | 4.99 | -3.71 | -3.98 | -1.20 | 4.88 | 12.05 | 10.14 | 8.18 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zynex, Inc. |
| Country |
United States |
| Employees |
283 |
| CEO |
Thomas Sandgaard |
Stock Information
| Ticker Symbol |
ZYXI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: ZYXI |
Description
Zynex, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.